Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jan 07, 2019
TickeronGET DAILY SIGNALS
Perkinelmer Just Hit Two Key Support Levels

Perkinelmer Just Hit Two Key Support Levels

Medical equipment manufacturer Perkinelmer (NYSE: PKI) has pulled back in the past few months, following the rest of the market. However, there could be good news for investors of Perkinelmer as the stock hit two key support levels in the last week.

We see on the daily chart that the stock dropped down to its 104-week moving average at its low last week, but then bounced sharply from there. The stock did the same thing back in early 2017 before jumping approximately 40% in the next six months.

The second support level that jumped out at me was the $72.50 area. We see that the stock struggled to get above that price in late 2017 before breaking through in early 2018. The stock then moved sideways from February through June, but it never closed a week below the $72.50 level during that stretch. I look for that price area to serve as strong support and look for the stock to bounce in the coming months.

In addition to the technical support, Perkinelmer has strong fundamental indicators as well. The company has seen earnings grow by 13% per year over the last three years. In the most recent quarterly report earnings grew by 23% while sales grew by 22%.

Even with the technical support and strong fundamentals, investors and analysts aren’t very bullish on the stock. There are 14 analysts following the stock and only five of them rank the stock as a “buy”. This leaves room for upgrades that can help propel the stock higher.

Related Ticker: RVTY

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for RVTY turns positive, indicating new upward trend

RVTY saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 65 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

The Aroon Indicator entered an Uptrend today. In 112 of 186 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.

Bearish Trend Analysis

The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 20 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.

The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.394) is normal, around the industry mean (67.298). P/E Ratio (74.572) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -1%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 40%. FLGT experienced the highest price growth at 36%, while BDSX experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 71% and the average quarterly volume growth was -93%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 45
SMR Rating: 78
Profit Risk Rating: 84
Seasonality Score: 20 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of analytical instruments

Industry MedicalSpecialties

Industry
Medical Specialties
Address
77 4th Avenue
Phone
+1 781 663-6900
Employees
11000
Web
https://www.revvity.com
Interact to see
Advertisement
SAN is Spain's largest bank with a diversified footprint across Europe and the Americas, while SMFG is Japan's second-largest lender anchored in a resurgent domestic banking market. Both names are riding structural tailwinds: SAN from efficiency gains and U.S./UK acquisitions, and SMFG from the Bank of Japan's rate-hiking cycle and the end of deflation.
RAPP fell -9.23% to about $26.66 during regular trading on Oct. 21, down from the prior close of $29.37. The decline unwinds Monday's brief post-trial pop as investors keep reassessing the Phase 2 RAP-219 bipolar mania results.
The central stock price target of $100 is the arithmetic mean of the verified analyst price targets reviewed; major aggregators report a similar consensus near $99–$102, with a wide range from roughly $60 to $150. With the stock trading near $53, reaching $100 would require a gain of approximately 88% — a very large move from current levels.
NVDA dropped from Friday's close of $186.64 to $174.06 intraday, down -6.74%, during regular market hours. The slide followed CEO Jensen Huang's admission of an extramarital affair and the board's independent investigation, announced November 8, after reports he was targeted by a suspected Chinese intelligence operative.
Barnes Group is expected to report its third quarter 2026 results around November 9–10, 2026, before the market opens. Consensus estimates point to earnings per share (EPS, a measure of profit divided by outstanding shares) of roughly $0.79, with revenue expectations near $5.16 billion, based on available analyst data.
Perkinelmer Just Hit Two Key Support Levels